DRUG DESIGN: A PRACTICAL APPROACH

May 14, 2009 – 2:01 pm

This book aims to put forth a strategy to facilitate the insightful design of new chemical entities as therapies for human disease—a strategy that will foster the ability to sit down in front of a blank computer screen and draw molecules that may help cure the various maladies that afflict humankind. This strategy uses a molecular-level understanding ofhuman biochemistry and pathology to drive the design of drug-like molecules engineered to fit precisely into targets of drug action (druggable targets).

A Drug as a Composite of Molecular Fragments For the practical implementation of this idealistic strategy, drug molecules are conceptualized as being assembled from biologically active building blocks (biophores) that are covalently “snapped together” to form an overall molecule. Thus, a drug molecule is a multiphore, composed of a fragment that enables it to bind to a receptor (pharmacophore), a fragment that influences its metabolism in the body (metabophore), and one or more fragments that may contribute to toxicity (toxicophores).

The drug designer should have the ability to optimize the pharmacophore while minimizing the number of toxicophores. To achieve this design strategy, these fragments or building blocks may be replaced or nterchanged to modify the drug structure. Certain building blocks (called bioisosteres), which are biologically equivalent but not necessarily chemically equivalent, may be used to promote the optimization of the drug’s biological properties.

DRUG DESIGN: THE HUMANITARIAN APPROACH
In traditional medicine there are two major therapeutic approaches to the treatment of human disease: surgical and medical. Surgical procedures are labour intensive and time demanding; they help a limited number of individuals, one at a time, mostly in rich or developed nations.

Medical therapy, on the other hand, is based on drug molecules and thus has the capacity to positively influence the lives of more people, often over a shorter time frame. Medical therapeutics offer hope in both developed and developing parts of the world—hopefully to rich and poor alike.

After public health measures (e.g., safe drinking water, hygienic disposal of waste water), the discovery of drugs has had one of the largest beneficial effects on human health. Penicillin has saved countless lives through the effective treatment of devastating infectious diseases. Before penicillin, a diagnosis of meningococcal meningitis was invariably a death sentence. Penicillin reduced bacterial meningitis to a treatable disorder.

Similarly, drugs for the treatment of high blood pressure have substantially reduced the impact of this “silent killer” that leads to myocardial infarction (heart attack) or cerebral infarction (stroke).

It can be awe-inspiring to witness the effects of a seemingly trivial amount of drug. The panic-stricken child who cannot breathe because of an asthma attack gets prompt relief from the inhalation of a mere 100 micrograms of salbutamol sulphate. Uncontrolled and potentially life-threatening seizures (status epilepticus) in a young adult are quickly brought under control with the intravenous administration of 2 mg of lorazepam.

The terrified older adult with crushing chest pain from a myocardial infarction gains rapid relief from 8 to 10 mg of morphine. Drugs are truly amazing molecules. A medicinal chemist can help thousands or even millions of people with a carefully designed new drug molecule. The practice of science is a very human activity; medicinal chemistry is a humanitarian science.


Introduction in Medical Chemistry

May 14, 2009 – 1:51 pm

Designing drug molecules to alleviate human disease and suffering is a daunting yet exhilarating task. How does one do it? How does a researcher sit down, paper in hand (or, better yet, a blank computer screen), and start the process of creating a molecule as a potential drug with which to treat human disease? What are the thought processes?

What are the steps? How does one select a target around which to design a drug molecule? When a researcher does design a molecule, how does she or he know if it has what it takes to be a drug?

These are important questions. The previous century ended with an explosion of activity in gene-related studies and stem cell research; the new one is emerging as the “Century of Biomedical Research.”We have now witnessed the global spectre of SARS (Severe Acute Respiratory Syndrome) and avian flu, which has emphasized the looming importance of infectious disease to global health.

Concerns about the capacity of “Mad Cow” disease to infect humans have focused attention on the safety of our food supply. AIDS and obesity-related disorders have not gone away, but rather are increasing in incidence and prevalence. Long-recognized diseases, such as stroke and Alzheimer’s dementia, are becoming more common as a greater proportion of the human population reaches old age.

Not surprisingly, the need for drug discovery to address these important diseases is increasingly being recognized as a societal priority. Not only is drug discovery important to the medical health of humankind, it is also an important component of our economic health. New chemical entities (NCEs) as therapeutics for human disease may become the “oil and gas” of the 21st century. As the world’s population increases and health problems expand accordingly, the need to discover new therapeutics will become even more pressing. In this effect, the design of drug molecules arguably offers some of the greatest hopes for success.


Drugs for AIDS/HIV

May 10, 2009 – 7:05 am

AIDS caused by the replication of the human immunodeficiency virus (HIV). It is susceptible to targeted interventions, because several virus specific metabolic steps occur in infected cells (A). Viral RNA must first be transcribed into DNA, a step catalyzed by viral “reverse transcriptase.” Doublestranded DNA is incorporated into the host genome with the help of viral integrase. Under control by viral DNA, viral replication can then be initiated, with synthesis of viral RNA and proteins (including enzymes such as reverse transcriptase and integrase, and structural proteins such as the matrix protein lining the inside of the viral envelope). These proteins are assembled not individually but in the form of polyproteins. These precursor proteins carry an N-terminal fatty acid (myristoyl) residue that promotes their attachment to the interior face of the plasmalemma. As the virus particle buds off the host cell, it carries with it the affected membrane area as its envelope. During this process, a protease contained within the polyprotein cleaves the latter into individual, functionally active proteins.

I. Inhibitors of Reverse Transcriptase
IA. Nucleoside agents
Nucleoside agents are analogues of thymine (azidothymidine, stavudine), adenine (didanosine), cytosine (lamivudine, zalcitabine), and guanine (carbovir, a metabolite of abacavir). They have in common an abnormal sugar moiety. Like the natural nucleosides, they undergo triphosphorylation, giving rise to nucleotides that both inhibit reverse transcriptase and cause strand breakage following incorporation into viral DNA.

The nucleoside inhibitors differ in terms of 1) their ability to decrease circulating HIV load; 2) their pharmacokinetic properties (half life—>dosing interval—>compliance; organ distribution—>passage through blood-brainbarrier); 3) the type of resistance-inducing mutations of the viral genome and the rate at which resistance develops; and 4) their adverse effects (bone marrow depression, neuropathy, pancreatitis).

IB. Non-nucleoside inhibitors
The non-nucleoside inhibitors of reverse transcriptase (nevirapine, delavirdine, efavirenz) are not phosphorylated. They bind to the enzyme with high selectivity and thus prevent it from adopting the active conformation. Inhibition is noncompetitive.

II. HIV protease inhibitors
Viral protease cleaves precursor proteins into proteins required for viral replication. The inhibitors of this protease (saquinavir, ritonavir, indinavir, and nelfinavir) represent abnormal proteins that possess high antiviral efficacy and are generally well tolerated in the short term. However, prolonged administration is associated with occasionally severe disturbances of lipid and carbohydrate metabolism. Biotransformation of these drugs involves cytochrome P450 (CYP 3A4) and is therefore subject to interaction with various other drugs inactivated via this route.

For the dual purpose of increasing the effectiveness of antiviral therapy and preventing the development of a therapy-limiting viral resistance, inhibitors of reverse transcriptase are combined with each other and/or with protease inhibitors.

Combination regimens are designed in accordance with substancespecific development of resistance and pharmacokinetic parameters (CNS penetrability, “neuroprotection,” dosing frequency).

source: Lullmann. 2000. Color Atlas of Pharmacology. Thieme
further information, please read this book.


Phenylpropanolamine (PPA) in Indonesia

April 25, 2009 – 10:06 am

BPOM (Drug and Food Superintendant Agency) Indonesia never removed phenylpropanolamine or PPA which is contained in cough or flu drugs in Indonesia. To perceive this issue, BPOM said that drugs contain PPA were allowed to using and marketing in Indonesia. The dosis permitted is 15 mg for cough and flu drugs [1].

As we know, PPA was removed in America because it increase risk of hemorrhagic stroke since November 2000 [2]. This is based on the research which be held in Yale University School of Medicine that result bleeding into the brain or into tissue surrounding the brain (hemorrhagic stroke) in women. Medicines which contain phenylpropanolamine should not consume for longer than 7 days if the condition does not improve or if the symptoms are accompanied by a high fever [3].

There are many drugs in Indonesia which contain phenylpropanolamine. For our health in the future, we should becareful to consume cough or flu drugs which contain PPA. Maybe, seeing the ingredient of the drugs which is the best choiche for preventing the bad side effect in our helath.

[1] http://kesehatan.kompas.com
[2] http://www.fda.gov/cder/drug/infopage/ppa/advisory.htm
[3] http://www.drugs.com/mtm/phenilpropanolamine.htm


Phenylpropanolamine (PPA) Hot Issue: Hoax or Fact?

April 25, 2009 – 10:05 am

Several days ago, there is an issue that Food and Drug Administration (FDA) was issued a "Public Health Advisory" which take steps to remove phenylpropanolamine from all drug products and has requested that all drug companies discontinue marketing products containing it.

Based on the issue, FDA  was issued this advisory on March 1st 2009. So, everything which contains phenylpropanolamine, such as DECOLGEN, DECOLSIN, SINUTAB, ALLERIN, BODREXIN, CONTAC 500, COSYR, FLUCYL, FLUDANE, FLUGESIC, INZA, KOMIX, MIXAFLU, MIXAGRIP, NALGESTAN, NEOZEP FORTE, NODROF, PARASUTIN, PROCOLD, RHINOTUSSAL, SANAFLU, SILADEX, STOPCOLD, TRIAMIN. Is it true that they are contain phenylpropanolamine (PPA)? To answer this question, please check it at links.

After I search on Google, this issue is an hoax. Why? Because FDA is not issued a "Public Health Advisory" about PPA at 1 March 2009. That is true if the the date was on November 2000.

To study about phenylpropanolamine:
1. What is the phenylpropanolamine?
2. Is it harmful for our health?
3. Why FDA issued a "Public Health Advisory" about phenylpropanolamine?
4. How about drugs are usually we used to against cough or flu?

and many facts else? Please click this phenylpropanolamine article.


Phenylpropanolamine (PPA) causing stroke?

April 25, 2009 – 10:01 am

What is phenylpropanolamine (PPA)?
Phenylpropanolamine is a drug ingredient of the phenethylamine family [1]. It used as a decongestant. It means that phenylpropanolamine used to treat the congestion associated with allergies, hay fever, sinus irritation, and the common cold [2]. It also causes a decrease in appetite and is used in some over-the-counter diet aids. In veterinary medicine, it is used to control urinary incontinence in dogs and is sold under brand names Propalin and Proin.

How phenylpropanolamine works?
Phenylpropanolamine will constric (shrink) blood vessels (veins and arteries) in the body. Constriction of blood vessels in sinuses, nose, and chest allows drainage of those areas, which decreases congestion.

Is phenylpropanolamine harmful for our health?
I has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women [3]. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine because of the seriousness of a stroke and the inability to predict who was at risk [4].

The public health advisory supported by the research of phenylpropanolamine at the Yale University School of Medicine in 1999  which was produced that PPA increased risk of hemmorrhagic stroke. This similar reports of cases had been circulating since the 1970s.

The sides effect of PPA.
Beside increased a hemorrhagic stroke, phenylpropanolamine also an allergic reaction (difficulty breathing; closing of your throat; swelling lips, tongue, or face; or hives); seizures; unusual behavior or hallucinations; or an irregular or fast heartbeat. Also, less serious side effects maybe occured like dizziness, lightheadedness, or drowsiness; headache; insomnia; anxiety; tremor (shaking) or restlessness; nausea or vomiting; or sweating.

[1] Flavahan NA. 2005. Phenylpropanolamine constricts mouse and human blood vessels by preferentially activating alpha2-adrenoceptors. J. Pharmacol. Exp. Ther. 313 (1): 432–9.

[2] http://www.drugs.com/mtm/phenilpropanolamine.htm
[3] Kernan WN et al. 2000. Phenylpropanolamine and the risk of hemorrhagic stroke. N. Engl. J. Med. 343 (25): 1826–32.
[4] http://www.fda.gov/cder/drug/infopage/ppa/advisory.htm


What is the medical biochemistry?

April 22, 2009 – 7:53 am

At the previous posting we were known by that about biochemistry. Now, we will learn one of the branchs of Biochemistry as the object study. In this part, we learn that biochemistry is also related to the medical. It’s called medical biochemistry or clinical biochemistry.

As we know, health science is like medical that it close to the cell. And, the cell is close to the Biochemistry. In medical biochemistry, we will study how food that we eat everyday can be utilised by our body. Furthermore, how the process of this utilization in our body, especially in our cells.

Medical biochemistry also study the mechanism of what kind of symptomps hold in our body and caused illness or sickness. This is a good sounds, so we can predict how diseases spreads or something infects our body and then make the body illness. So, if we know the disease mechanisms, we will assume any hypotheses how to against the sickness caused factors.

These informations is supported with the facts. There are avian influenza (H5N1) cases, mutagenic avian influenza viruses, HIV viruses or AIDS viruses, and many more. When medical biochemistry is used in this cases, there will be known about what, why, and how these are occured. Furthermore, we also will know how to avoid and against the caused factor pr these diseases.

So, are you interest in medical biochemistry?